WuXi NextCODE to Offer The New Pan-Cancer TSO 500 Biomarker Assay from Illumina
WuXi NextCODE offers access to Illumina's TruSightTM Oncology 500 (TSO 500).
WuXi NextCODE has extended and completed a Series B round with investment from a consortium led by Sequoia China and including Temasek, Yunfeng Capital and 3W Partners.
Brainin joins the company from Illumina, where he was Vice President and General Manager of Life Sciences and Applied Genomics.
Some 7,500 rare disorders are known to be caused by single gene mutations. A vast majority of these disorders first appear at birth or in early childhood. For half of these conditions, the responsible gene has been identified. Yet the family of a child with one of these disorders spends an average of 12 years searching before finding a correct diagnosis.
The first trial of WuXi NextCODE's whole-genome sequencing consumer product, HealthCODE, demonstrates the potential for WGS to support health and wellness.
Using whole-exome sequencing and chromosome microarray analyses, researchers at Boston Children's Hospital explore the genetic variants responsible for early-onset psychosis.